7/102 sources · 2 publishersUpdated Nov 12, 22:36 UTC
Alumis posts Q3 2026 loss of $94.9 million as revenue falls 8%
Alumis reported third‑quarter 2026 revenue of $1.91 million, an 8% decline year‑over‑year. The quarter ended with a net loss of $94.88 million, better than the $110.8 million loss recorded in Q3 2025. Research and development expenses dropped 17% as clinical trials were completed. The company said it will file an NDA for its envu psoriasis candidate by year‑end and is evaluating strategic alternatives for lonigutamab.
Why it matters
The narrowed loss may reduce immediate financing pressure, but the very low revenue underscores ongoing cash‑flow challenges. The pending NDA filing could create a catalyst for the stock if approved.
Key facts
- 1Q3 2026 revenue was $1.91 million, down 8% YoY. tradingview.com
- 2Net loss for Q3 2026 was $94.88 million. tradingview.com
- 3Net loss improved from $110.8 million in Q3 2025. seekingalpha.com
- 4R&D expenses fell 17% YoY. tradingview.com
- 5The company plans an NDA submission for envu in psoriasis by year‑end. tradingview.com
- 6Alumis is exploring strategic alternatives for lonigutamab. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.